Dear AuntMinnie Member,
The U.S. Food and Drug Administration (FDA) is planning to relax its regulatory requirements for full-field digital mammography (FFDM) systems in a move that could make it easier for new FFDM technologies to get to market.
In an article in our Women's Imaging Digital Community, staff writer Cynthia Keen describes how the FDA's proposal would eliminate the requirement that new FFDM systems go through the premarket approval (PMA) process before they can be sold in the U.S. The PMA process is more cumbersome and requires clinical trials, unlike the 510(k) process used for most radiology devices.
Vendors are applauding the move, saying that it would enable companies to commercialize new FFDM technologies much more quickly -- perhaps in as few as 90 days. Find out how it could affect breast imaging providers by clicking here, or go to the Women's Imaging Digital Community at women.auntminnie.com.


















![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&fit=crop&h=112&q=70&w=112)
